Literature DB >> 10516016

Identification of functional domains in the 14-kilodalton envelope protein (A27L) of vaccinia virus.

M I Vázquez1, M Esteban.   

Abstract

The mechanism of entry of vaccinia virus (VV) into cells is still a poorly understood process. A 14-kDa protein (encoded by the A27L gene) in the envelope of intracellular mature virus (IMV) has been implicated in virus-cell attachment, virus-cell fusion, and virus release from cells. We have previously described the structural organization of the VV 14-kDa protein, consisting of a triple-stranded coiled-coil region responsible for oligomer formation and a predicted Leu zipper-like third alpha helix with an important role in the interaction with a 21-kDa membrane protein (encoded by the A17L gene) thought to anchor the 14-kDa protein to the envelope of IMV (M.-I. Vázquez, G. Rivas, D. Cregut, L. Serrano, and M. Esteban, J. Virol. 72:10126-10137, 1998). To identify the functional domains important for virus entry and release, we have generated VV recombinants containing a copy of the A27L gene regulated by the lacI operator-repressor system of Escherichia coli (VVIndA27L) in the thymidine kinase locus and a mutant form of the A27L gene in the hemagglutinin locus but expressed constitutively under the control of an early-late VV promoter. Cells infected with a VV recombinant that expresses a mutant 14-kDa form lacking the first 29 amino acids at the N terminus failed to form extracellular enveloped virus (EEV). Fusion-from-without assays with purified virus confirmed that the fusion process was mediated by the 14-kDa protein and the fusion domain to be contained within amino acids 29 to 43 of the N-terminal region. Competitive inhibition of the infection process with soluble heparin and synthetic peptides and in vitro experiments with purified mutant proteins identified the heparin binding domain within amino acids 21 to 33, suggesting that this domain is involved in virus-cell binding via heparan sulfate. Thus, the N terminus of the 14-kDa protein contains a heparin binding domain, a fusion domain, and a domain responsible for interacting with proteins or lipids in the Golgi stacks for EEV formation and virus spread.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10516016      PMCID: PMC112942     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Intracellular and extracellular vaccinia virions enter cells by different mechanisms.

Authors:  A Vanderplasschen; M Hollinshead; G L Smith
Journal:  J Gen Virol       Date:  1998-04       Impact factor: 3.891

2.  Initial interaction of herpes simplex virus with cells is binding to heparan sulfate.

Authors:  D WuDunn; P G Spear
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

3.  Molecular modeling of protein-glycosaminoglycan interactions.

Authors:  A D Cardin; H J Weintraub
Journal:  Arteriosclerosis       Date:  1989 Jan-Feb

4.  A 14,000-Mr envelope protein of vaccinia virus is involved in cell fusion and forms covalently linked trimers.

Authors:  J F Rodriguez; E Paez; M Esteban
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

Review 5.  The CD4 antigen: physiological ligand and HIV receptor.

Authors:  Q J Sattentau; R A Weiss
Journal:  Cell       Date:  1988-03-11       Impact factor: 41.582

6.  Biogenesis of poxviruses: role of A-type inclusions and host cell membranes in virus dissemination.

Authors:  Y Ichihashi; S Matsumoto; S Dales
Journal:  Virology       Date:  1971-12       Impact factor: 3.616

7.  Isolation and characterization of neutralizing monoclonal antibodies to vaccinia virus.

Authors:  J F Rodriguez; R Janeczko; M Esteban
Journal:  J Virol       Date:  1985-11       Impact factor: 5.103

8.  Heparan sulfate proteoglycan binding by herpes simplex virus type 1 glycoproteins B and C, which differ in their contributions to virus attachment, penetration, and cell-to-cell spread.

Authors:  S Laquerre; R Argnani; D B Anderson; S Zucchini; R Manservigi; J C Glorioso
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  Defective vaccinia virus particles in interferon-treated infected cells.

Authors:  M Esteban
Journal:  Virology       Date:  1984-02       Impact factor: 3.616

10.  Golgi-derived membranes that contain an acylated viral polypeptide are used for vaccinia virus envelopment.

Authors:  G Hiller; K Weber
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

View more
  24 in total

1.  The fusion domain of HIV gp41 interacts specifically with heparan sulfate on the T-lymphocyte cell surface.

Authors:  J Cladera; I Martin; P O'Shea
Journal:  EMBO J       Date:  2001-01-15       Impact factor: 11.598

2.  Effects of deletion or stringent repression of the H3L envelope gene on vaccinia virus replication.

Authors:  F G da Fonseca; E J Wolffe; A Weisberg; B Moss
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

3.  Characterization of the vaccinia virus H3L envelope protein: topology and posttranslational membrane insertion via the C-terminal hydrophobic tail.

Authors:  F G da Fonseca; E J Wolffe; A Weisberg; B Moss
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

4.  Adaptation of tick-borne encephalitis virus to BHK-21 cells results in the formation of multiple heparan sulfate binding sites in the envelope protein and attenuation in vivo.

Authors:  C W Mandl; H Kroschewski; S L Allison; R Kofler; H Holzmann; T Meixner; F X Heinz
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

5.  Vaccinia virus G9 protein is an essential component of the poxvirus entry-fusion complex.

Authors:  Suany Ojeda; Arban Domi; Bernard Moss
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

6.  Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.

Authors:  Aklile Berhanu; Rebecca L Wilson; Dana L Kirkwood-Watts; David S King; Travis K Warren; Susan A Lund; Lindsay L Brown; Alex K Krupkin; Erin Vandermay; Will Weimers; Kady M Honeychurch; Douglas W Grosenbach; Kevin F Jones; Dennis E Hruby
Journal:  J Virol       Date:  2008-01-16       Impact factor: 5.103

7.  Vaccinia virus A21 virion membrane protein is required for cell entry and fusion.

Authors:  Alan C Townsley; Tatiana G Senkevich; Bernard Moss
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

8.  Identification and characterization of three immunodominant structural proteins of fowlpox virus.

Authors:  Denise Boulanger; Philip Green; Brenda Jones; Gwenn Henriquet; Lawrence G Hunt; Stephen M Laidlaw; Paul Monaghan; Michael A Skinner
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  A differential role for macropinocytosis in mediating entry of the two forms of vaccinia virus into dendritic cells.

Authors:  Kerrie J Sandgren; John Wilkinson; Monica Miranda-Saksena; Gerald M McInerney; Karen Byth-Wilson; Phillip J Robinson; Anthony L Cunningham
Journal:  PLoS Pathog       Date:  2010-04-22       Impact factor: 6.823

10.  Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization.

Authors:  Kaori Shinoda; Linda S Wyatt; Kari R Irvine; Bernard Moss
Journal:  Virol J       Date:  2009-03-03       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.